270 related articles for article (PubMed ID: 22804572)
1. Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.
Kornbluth RS; Stempniak M; Stone GW
Int Rev Immunol; 2012 Aug; 31(4):279-88. PubMed ID: 22804572
[TBL] [Abstract][Full Text] [Related]
2. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
Vitale LA; Thomas LJ; He LZ; O'Neill T; Widger J; Crocker A; Sundarapandiyan K; Storey JR; Forsberg EM; Weidlick J; Baronas AR; Gergel LE; Boyer JM; Sisson C; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2019 Feb; 68(2):233-245. PubMed ID: 30382327
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties.
Ceglia V; Zurawski S; Montes M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
J Immunol; 2021 Oct; 207(8):2060-2076. PubMed ID: 34551965
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders.
Chand Dakal T; Dhabhai B; Agarwal D; Gupta R; Nagda G; Meena AR; Dhakar R; Menon A; Mathur R; Mona ; Yadav V; Sharma A
Immunobiology; 2020 Mar; 225(2):151899. PubMed ID: 31899051
[TBL] [Abstract][Full Text] [Related]
5. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
Carpenter EL; Mick R; Rüter J; Vonderheide RH
J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
[TBL] [Abstract][Full Text] [Related]
6. The role of CD40 and CD154/CD40L in dendritic cells.
Ma DY; Clark EA
Semin Immunol; 2009 Oct; 21(5):265-72. PubMed ID: 19524453
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
[TBL] [Abstract][Full Text] [Related]
8. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
Richman LP; Vonderheide RH
Cancer Immunol Res; 2014 Jan; 2(1):19-26. PubMed ID: 24416732
[TBL] [Abstract][Full Text] [Related]
9. CD40 activation as potential tool in malignant neoplasms.
Ottaiano A; Pisano C; De Chiara A; Ascierto PA; Botti G; Barletta E; Apice G; Gridelli C; Iaffaioli VR
Tumori; 2002; 88(5):361-6. PubMed ID: 12487551
[TBL] [Abstract][Full Text] [Related]
10. CD40-activated B cells contribute to mesothelioma tumor regression.
Jackaman C; Cornwall S; Graham PT; Nelson DJ
Immunol Cell Biol; 2011 Feb; 89(2):255-67. PubMed ID: 20628372
[TBL] [Abstract][Full Text] [Related]
11. Generation of human CD40-activated B cells.
Liebig TM; Fiedler A; Zoghi S; Shimabukuro-Vornhagen A; von Bergwelt-Baildon MS
J Vis Exp; 2009 Oct; (32):. PubMed ID: 19838159
[TBL] [Abstract][Full Text] [Related]
12. Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance.
Pinelli DF; Ford ML
Immunotherapy; 2015; 7(4):399-410. PubMed ID: 25917630
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism and function of CD40/CD40L engagement in the immune system.
Elgueta R; Benson MJ; de Vries VC; Wasiuk A; Guo Y; Noelle RJ
Immunol Rev; 2009 May; 229(1):152-72. PubMed ID: 19426221
[TBL] [Abstract][Full Text] [Related]
14. Tuning of CD40-CD154 interactions in human B-lymphocyte activation: a broad array of in vitro models for a complex in vivo situation.
Néron S; Nadeau PJ; Darveau A; Leblanc JF
Arch Immunol Ther Exp (Warsz); 2011 Feb; 59(1):25-40. PubMed ID: 21234809
[TBL] [Abstract][Full Text] [Related]
15. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application.
von Bergwelt-Baildon MS; Vonderheide RH; Maecker B; Hirano N; Anderson KS; Butler MO; Xia Z; Zeng WY; Wucherpfennig KW; Nadler LM; Schultze JL
Blood; 2002 May; 99(9):3319-25. PubMed ID: 11964299
[TBL] [Abstract][Full Text] [Related]
16. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
17. The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells.
Shimabukuro-Vornhagen A; Draube A; Liebig TM; Rothe A; Kochanek M; von Bergwelt-Baildon MS
J Exp Clin Cancer Res; 2012 May; 31(1):47. PubMed ID: 22592077
[TBL] [Abstract][Full Text] [Related]
18. Agonistic CD40 antibodies and cancer therapy.
Vonderheide RH; Glennie MJ
Clin Cancer Res; 2013 Mar; 19(5):1035-43. PubMed ID: 23460534
[TBL] [Abstract][Full Text] [Related]
19. B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses.
Rossetti RAM; Lorenzi NPC; Yokochi K; Rosa MBSF; Benevides L; Margarido PFR; Baracat EC; Carvalho JP; Villa LL; Lepique AP
PLoS One; 2018; 13(7):e0199034. PubMed ID: 29975708
[TBL] [Abstract][Full Text] [Related]
20. APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application.
Filbert EL; Björck PK; Srivastava MK; Bahjat FR; Yang X
Cancer Immunol Immunother; 2021 Jul; 70(7):1853-1865. PubMed ID: 33392713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
